AMLX · Amylyx Pharmaceuticals, Inc.
$27.20
-4.79% last session
End-of-day data · close of 2026-10-23
Market cap
$3B
Enterprise value
$3B
Trailing P/E
—
Forward P/E
-24.9
Dividend yield
0.0%
Beta
-0.09
Avg volume
2M
Employees
0K
Daily Change %
-4.79%
5 Days Change
-0.48%
10 Days Change
0.63%
30 Days Change
-9.75%
60 Days Change
-27.39%
Month to Day Change
-3.13%
Year to Day Change
125.17%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — AMLX
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-15
Latest call per bank · past 12 months
Citigroup
Buy$39.00
+43.4% vs priceBank of America
Buy$19.00
-30.1% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-15 | Citigroup | Maintains | Buy | $32.00 → $39.00 |
| 2026-08-27 | Guggenheim | Maintains | Buy | $55.00 → $57.00 |
| 2026-08-19 | Mizuho | Maintains | Outperform | $30.00 → $42.00 |
| 2026-08-19 | Guggenheim | Maintains | Buy | $40.00 → $55.00 |
| 2026-08-19 | Baird | Maintains | Outperform | $28.00 → $52.00 |
| 2026-08-18 | HC Wainwright & Co. | Maintains | Buy | $34.00 → $55.00 |
| 2026-08-17 | Mizuho | Maintains | Outperform | $24.00 → $30.00 |
| 2026-08-03 | Citigroup | Maintains | Buy | $20.00 → $26.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 43 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 12.8% below the 50-day MA ($31.20).
- bullish: Price vs 200-day MA: Trading 38.1% above the 200-day MA ($19.69).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.14) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($11.38) and high ($39.66).
AMLX Price Chart
Loading chart for AMLX…
Fundamentals
About Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
More in Drug Manufacturers - Specialty & Generic
TAK
Takeda Pharmaceutical Company L
$65B 30.6% YTD
TEVA
Teva Pharmaceutical Industries
$46B 28.8% YTD
HLN
Haleon plc
$45B 4.6% YTD
ZTS
Zoetis Inc.
$33B -33.8% YTD
UTHR
United Therapeutics Corporation
$25B 20.0% YTD
VTRS
Viatris Inc.
$21B 51.9% YTD
NBIX
Neurocrine Biosciences, Inc.
$15B 1.0% YTD
ELAN
Elanco Animal Health Incorporat
$11B 0.3% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.